$23.650
+0.336 (+1.42%)At close
KIDS News
KIDS Events
OrthoPediatrics Launches Traxio Complete Weight System
OrthoPediatrics announced the launch of the Traxio Complete Weight System, in collaboration with Synetik Group, Inc. "The introduction of TRAXIO reflects our ongoing commitment to advancing pediatric scoliosis through thoughtful innovation," said Joe Hauser, OrthoPediatrics specialty bracing division president. "TRAXIO offers a reliable, adaptable traction system that supports patient safety while reinforcing our focus on important solutions often overlooked by others, and meaningfully extends the continuum of care from bracing through surgery when needed."
OrthoPediatrics Q1 Revenue $59.36M, Exceeds Expectations
Reports Q1 revenue $59.36M, consensus $58.32M. David Bailey, President & CEO of OrthoPediatrics, commented, "We delivered a strong start to 2026 with 13% first quarter revenue growth and significant improvement in adjusted EBITDA and free cash flow, reflecting solid execution across the business. Momentum built throughout the quarter and was driven by broad-based strength, including robust international performance and OPSB growth supported by new products and clinic expansion. We are successfully scaling OPSB, taking share in our surgical business, and advancing innovative product launches, while improving profitability and remaining on track to meet our adjusted EBITDA goals. Looking ahead, we are entering a highly compelling phase, underpinned by a multi-year product super cycle expected to drive higher ASPs, margin expansion, and improved returns, while enhancing our ability to deepen hospital partnerships, and strengthen our leadership in pediatric care."
OrthoPediatrics Partner iotaMotion Receives FDA Clearance for Expanded Pediatric Use
OrthoPediatrics announced its partner, iotaMotion, has received FDA 510(k) clearance for expanded pediatric use of its iotaSOFT Insertion System. The system is now cleared for use in patients four years of age and older, extending access to robotic-assisted cochlear implantation for school-aged children. "This milestone allows us to leverage our existing capabilities and bring the same discipline, focus, and pediatric-first expertise beyond orthopedics. We are excited to extend our ability to help more children through improved clinical care and efficiency in the ENT space with an advanced technology like iotaSOFT," commented David Bailey, President & CEO of OrthoPediatrics.
Generated Company Reports $236.1M Net Revenue for 2025
Generated record preliminary unaudited full year 2025 net revenue of $236.1M, representing continued growth compared to $204.7M in 2024 of 15%. Preliminary full year domestic net revenue is expected to be $186.2M, representing 16% annual growth and international net revenue is expected to be $49.9M, representing 15% annual growth. Generated preliminary unaudited fourth quarter 2025 net revenue of $61.3M, representing 16% growth compared to $52.7M in the fourth quarter of 2024. Preliminary domestic fourth quarter net revenue is expected to be $48.4M, representing 13% growth compared to the prior year period, and international net revenue is expected to be $12.9M, representing 32% growth compared to the prior year period. Generated approximately $6M - $7M of fourth quarter 2025 free cash flow, resulting in total year 2025 free cash flow usage being over 50% lower than total year 2024.
OrthoPediatrics Projects 2026 Revenue of $262M to $266M
OrthoPediatrics projects 2026 revenue to be in the range of $262M to $266M, representing 11% to 13% growth compared to full year 2025 preliminary unaudited net revenue. The Company also expects approximately $10M annual set deployment and expects to generate approximately $25M Adjusted EBITDA in 2026. "Throughout 2025, we delivered another year of strong performance, advanced our strategic initiatives, and widened our leadership position in pediatric orthopedics. Our Trauma and Deformity and Scoliosis implant businesses continued to execute effectively, taking market share, driving topline revenue, and improving profitability," commented David Bailey, President & CEO of OrthoPediatrics. "We are also extremely pleased with the specialty bracing business, which remains a tremendous market opportunity and a strategic catalyst for deepening customer relationships. OPSB is proving to be a capital-efficient driver of both revenue and earnings, and we are only beginning to unlock its full potential as we scale in the years ahead. In 2025, we helped over 37,500 children in the fourth quarter alone and nearly 1.3 million since inception, while generating record preliminary unaudited revenue growth of 15% from 2024, and significantly reducing free cash flow usage year-over-year. Looking forward, we are confident that our growth drivers and operational discipline position us to execute on our long-term outlook and continue making a meaningful impact for children worldwide."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.